Product Description
ReNetX Bio is developing AXER-204 as a treatment for Chronic Spinal Cord Injury. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT03989440)
Mechanisms of Action: MAG Inhibitor
Novel Mechanism: Yes
Modality: Fusion Protein
Route of Administration: N/A
FDA Designation: Fast Track - Spinal Cord Injuries *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: ReNetX Bio
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Spinal Cord Injuries
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03989440 |
RESET | P2 |
Completed |
Spinal Cord Injuries |
2022-06-21 |
21% |
2022-08-19 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |